RT Journal Article
SR Electronic
T1 Aerosolizable plasmid DNA dry powders engineered by thin-film freezing
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.10.03.510625
DO 10.1101/2022.10.03.510625
A1 Haiyue Xu
A1 Chaeho Moon
A1 Sawittree Sahakijpijarn
A1 Huy M. Dao
A1 Riyad F. Alzhrani
A1 Jie-liang Wang
A1 Robert O. Williams III
A1 Zhengrong Cui
YR 2022
UL http://biorxiv.org/content/early/2022/10/07/2022.10.03.510625.abstract
AB This study was designed to test the feasibility of using thin-film freezing (TFF) to prepare aerosolizable dry powders of plasmid DNA (pDNA) for pulmonary delivery. Dry powders of pDNA formulated with mannitol/leucine (70/30, w/w) at various of drug loadings, solid contents, and solvents were prepared using TFF, their aerosol properties (i.e., mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF)) determined, and selected powders were used for further characterization. Of the nine dry powders prepared, their MMAD values were about 1-2 mm, with FPF values (delivered) of 40-80%. The aerosol properties of the powders were inversely correlated with the pDNA loading and the solid content in the pDNA solution before thin-film freezing. Powders prepared with Tris-EDTA (TE) buffer or cosolvents (i.e., 1,4 dioxane or t-butanol in water), instead of water, showed slightly reduced aerosol properties. Ultimately, powders prepared with pDNA loading at 5% (w/w), 0.25% of solid content, with or without TE were selected for further characterization due to their overall good aerosol performance. The pDNA powders exhibited a porous matrix, crystalline structure, with a moisture content of <2% (w/w). Agarose gel electrophoresis confirmed the chemical integrity of the pDNA after it was subjected to TFF and after the TFF powder was actuated. A cell transfection study confirmed the activity of the pDNA after it was subjected to TFF. In conclusion, it is feasible to use TFF to produce aerosolizable pDNA dry powder for pulmonary delivery, while preserving the integrity and activity of the pDNA.Competing Interest StatementCui reports a relationship with TFF Pharmaceuticals, Inc. that includes equity or stocks and research funding. Williams reports a relationship with TFF Pharmaceuticals, Inc. that includes consulting or advisory, equity or stocks, and research funding. Xu and Moon report a relationship with TFF Pharmaceuticals, Inc. that includes: consulting or advisory. Financial conflict of interest management plans are available at UT Austin.